Patents Assigned to Prothena Biosciences Limited
-
Publication number: 20190315843Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: ApplicationFiled: April 16, 2019Publication date: October 17, 2019Applicant: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Patent number: 10442855Abstract: The invention provides antibodies that specifically bind to medin. The antibodies have the capacity to bind to monomeric, misfolded, aggregated, fibril or deposited forms of medin. The antibodies can be used for treating or effecting prophylaxis of diseases associated with medin, medin accumulation or accumulation of medin deposits (e.g., medin amyloidosis). The antibodies can also be used for diagnosing medin amyloidosis and inhibiting or reducing aggregation of medin, among other applications.Type: GrantFiled: June 30, 2016Date of Patent: October 15, 2019Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Paul Joseph Shughrue, Tarlochan S. Nijjar
-
Patent number: 10414825Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.Type: GrantFiled: July 28, 2016Date of Patent: September 17, 2019Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
-
Publication number: 20190277863Abstract: The invention provides an infrared assay which allows the secondary structure analysis of alpha-synuclein from complex fluids like serum, blood plasma or cerebrospinal fluid without prior isolation, concentration or pretreatment. The secondary structure profile provides an indication of the proportion of alpha-synuclein in aggregated form and/or extent of aggregation of alpha-synuclein in aggregated form.Type: ApplicationFiled: December 1, 2017Publication date: September 12, 2019Applicant: PROTHENA BIOSCIENCES LIMITEDInventor: Robin BARBOUR
-
Patent number: 10407506Abstract: The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer.Type: GrantFiled: March 12, 2015Date of Patent: September 10, 2019Assignee: PROTHENA BIOSCIENCES LIMITEDInventor: Yue Liu
-
Patent number: 10407507Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.Type: GrantFiled: July 28, 2016Date of Patent: September 10, 2019Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
-
Publication number: 20190227082Abstract: The invention provides methods of detecting both total alpha-synuclein and S129 phosphorylated (pS129) alpha-synuclein using a donor complex, a first acceptor complex, and a second acceptor complex. The donor complex comprises an antibody that specifically binds to alpha-synuclein linked to a support and a donor label. The 4B12 antibody is an example of a suitable antibody in the donor complex. The first acceptor complex for detecting pS129 alpha-synuclein comprises an antibody that preferentially binds to pS129 alpha-synuclein linked to a support and a first acceptor label. The 11A5 antibody is an example of a suitable antibody in the first acceptor complex. The second acceptor complex for detecting alpha-synuclein comprises an antibody that binds to alpha-synuclein regardless of S129 phosphorylation. The LB509 antibody is an example of a suitable antibody in the second acceptor complex.Type: ApplicationFiled: July 6, 2017Publication date: July 25, 2019Applicant: PROTHENA BIOSCIENCES LIMITEDInventors: Robin BARBOUR, Deniz KIRIK, Natalie Regina LANDECK
-
Publication number: 20190169280Abstract: Antibody formulations and methods useful for treatment of peripheral neuropathy in patients with AL amyloidosis.Type: ApplicationFiled: June 30, 2017Publication date: June 6, 2019Applicant: PROTHENA BIOSCIENCES LIMITEDInventors: GENE G. KINNEY, SPENCER D. GUTHRIE, MARTIN KOLLER
-
Patent number: 10301382Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: GrantFiled: August 21, 2018Date of Patent: May 28, 2019Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Patent number: 10118960Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: GrantFiled: May 4, 2017Date of Patent: November 6, 2018Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Patent number: 10081674Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).Type: GrantFiled: February 10, 2017Date of Patent: September 25, 2018Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
-
Patent number: 10059761Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.Type: GrantFiled: March 12, 2015Date of Patent: August 28, 2018Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
-
Publication number: 20180237516Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.Type: ApplicationFiled: February 9, 2018Publication date: August 23, 2018Applicant: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Tarlochan S. Nijjar
-
Patent number: 9951131Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.Type: GrantFiled: July 11, 2014Date of Patent: April 24, 2018Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Tarlochan S. Nijjar
-
Patent number: 9884906Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.Type: GrantFiled: December 21, 2016Date of Patent: February 6, 2018Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Jose William Saldanha, Tarlochan S. Nijjar
-
Patent number: 9879071Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.Type: GrantFiled: September 5, 2012Date of Patent: January 30, 2018Assignee: Prothena Biosciences LimitedInventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
-
Patent number: 9879080Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.Type: GrantFiled: July 2, 2016Date of Patent: January 30, 2018Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORKInventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
-
Patent number: 9850302Abstract: The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.Type: GrantFiled: July 11, 2014Date of Patent: December 26, 2017Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Robin Barbour, Yue Liu
-
Publication number: 20170158755Abstract: The invention provides antibodies that specifically bind to the LG1-3 modules of the G domain of laminin ?4. The antibodies have the capacity to inhibit binding of laminin ?4 to MCAM. The antibodies can be used for inhibiting undesired immune responses, treatment of cancer, or treatment of obesity or obesity-related diseases, among other applications.Type: ApplicationFiled: March 12, 2015Publication date: June 8, 2017Applicant: Prothena Biosciences LimitedInventors: Kenneth Flanagan, Stephen Jed Tam, Yue Liu, Theodore Yednock, Robin Barbour
-
Patent number: 9670273Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: GrantFiled: November 10, 2015Date of Patent: June 6, 2017Assignee: PROTHENA BIOSCIENCES LIMITEDInventors: Jose Saldanha, Tarlochan S. Nijjar